Form 8-K - Current report:
SEC Accession No. 0001558370-24-014947
Filing Date
2024-11-08
Accepted
2024-11-08 06:55:20
Documents
15
Period of Report
2024-11-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ymab-20241108x8k.htm   iXBRL 8-K 36255
2 EX-99.1 ymab-20241108xex99d1.htm EX-99.1 252260
3 GRAPHIC ymab-20241108xex99d1001.jpg GRAPHIC 5043
  Complete submission text file 0001558370-24-014947.txt   435279

Data Files

Seq Description Document Type Size
4 EX-101.SCH ymab-20241108.xsd EX-101.SCH 3400
5 EX-101.LAB ymab-20241108_lab.xml EX-101.LAB 15927
6 EX-101.PRE ymab-20241108_pre.xml EX-101.PRE 10319
17 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20241108x8k_htm.xml XML 4845
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38650 | Film No.: 241437939
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)